Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017

Transcription

1 Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March

2 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE

3 From symptoms to molecular gene signatures Moving away from the onedrug-fits-all paradigm Segmentation of patients Targeted therapies versus standard treatments such as chemotherapy. 3

4 Targeting specific biomarkers - oncogenes An oncogene is a gene that has the potential to cause cancer. In tumor cells, they are often mutated or expressed at high levels Example: BRAF mutations occur in ~50% of melanoma or skin cancers. 4

5 Access to precision medicine today 5

6

7 Access to precision medicine with Idylla 7

8 8

9 Instrument Taking existing technologies to the next level Polymerase Chain Reaction (PCR) technology Console Miniaturization: lab-in-a-box, all reagents inside Automation Sensitivity to the limits Disposable cartridge

10 Any type of clinical sample

11 Fully automated sample to result

12 Access on demand

13 Speed and connectivity

14 Accurate results 14

15 Is the customer buying into innovation?

16 Customer survey revealed customer delight Oncologists, pathologists, molecular biologists and lab technicians who have experience with Idylla Six nationalities: UK, BE, IRE, SP, PORT, FR The number one argument for our setting is the short turn- around time. Patients lives are affected if not treated quickly; some patients only have months to live. A result in 1.5 hours means decisions can be made quickly and these decisions are well informed. The Idylla platform is a real game changer. Richard Sullivan, Division Manager IVD, Abacus (Australia and New Zealand) Molecular biologist UK 17

17

18 Innovation is a verb Innovatie is een werkwoord 19

19 Business strategy & innovation tightly connected Solid tumor sample to result solutions Liquid biopsy testing on same platform Pushing sensitivity for superior performance data of Idylla tests Proprietary content for immuno-oncology Dx Gateway to Next-Generation Sequencing (NGS) Customers o Installed base and cartridge volume growth o Deployment Idylla platform in research and clinical performance studies Pharmaceutical/biotech companies o Commercial collaborations o Porting of proprietary assays to Idylla TM o R&D collaborations o Companion diagnostics (CDx) * FFPE = formalin fixed paraffin embedded ~ [add source] 20

20 Liquid biopsy assays, a promising extension of our menu Cancerous tumors release cell-free circulating tumor ( ct ) DNA fragments into the bloodstream Circulating blood biomarkers are a promising surrogate for solid tumor tissue-based biomarkers as this approach: Allows for non-invasive sample taking Does not require prior information of the tumor location Is suitable for repeat sampling Combined offering of solid and liquid testing expected to deepen market adoption of Idylla Focus for 2017 and beyond on liquid biopsies on lung, colon and breast cancers: easy diagnostic inclusion and monitoring of resistance to therapy Promising market potential 21

21 Teaming up with Next Gen Sequencing (NGS) Enabling NGS through standardization and automation of key sample and library prep steps Complementing NGS Idylla as first line testing for patients with most common alterations, NGS for detection of less common alterations sample prep NGS library prep sequencing BRAF NRAS Other KRAS NRAS BRAF MSI Isolate genomic material from Target amplification via PCR clinical sample Indexing & tagging via PCR Quantify genomic material via Purification qpcr Pool libraries Sequencing Data analysis Melanoma** Colon Hands-on Total turn around time 2.5h 5h 3.5h 7h ** Source: Dienstmann, Salazar, and Tabernero ASCO EdBook 2015 and 22

22 Facts & figures 23

23 Test menu expansion Idylla follows a razor-razorblade model Cartridge consumption on Idylla instruments is key value driver of Biocartis A broad installed base of Idylla instruments with expanding Idylla test menu facilitates cartridge consumption Instrument installed base growth An increasing installed base will: Grow consumption of existing Idylla tests Accelerate market adoption of new Idylla tests 24

24 Executing on the promises Installed base Cartridge consumption Menu Installed base Idylla instruments more than doubled in 2016 by adding a total of 224 instruments Total installed base year end was close to 390 instruments. Commercial cartridge volume in 2016 increased to over 25,000 cartridges which represents approx. 7.5 times the total commercial volume of On market oncology menu expanded to 7 tests Revenues Cash position Product revenues in 2016 amounted to EUR 6.8m, representing +88% compared to 2015 Total 2016 operating income amounted to EUR 13.8m Cash and cash equivalents on 31 December 2016 amounted to EUR 83.2m 25

25 What to expect? 26

26 Solid basis for exponential growth expected installed base expansion in 2017 Forecasted total installed base of Idylla instruments around 640 by year-end Commercial cartridge volume in 2017 to be at least three times 2016 volume CE-marking of 4 existing tests (EGFR, NRAS, ct KRAS, ct NRAS-BRAF) Launch Idylla ctegfr Mutation Assay (RUO) US FDA 510(k) approval of the Idylla platform in conjunction with Idylla IFV-RSV Panel Test 27

27 Expanding in US Expected to account for largest proportion of MDx market for oncology (expected market size of $1.45B by 2020)* Requires more rigorous product clearance efforts, incl. Pre-Market Approvals (PMAs) for most oncology products Status: - US FDA 510(k) premarket notification approval filed for Idylla Instrument and Console, and for the Idylla Respiratory (IFV-RSV) Panel 2016 Phase 1: operational start H Phase 2: Idylla platform supporting RUO oncology assays - Idylla Instrument and Console may gain exemption from 510(k) requirements per the FDA Preliminary List of 510(K) Exempt Devices published 14Mar2017**. Final list of exempt devices anticipated to be published in July 2017 Phase 3: PMAs for our oncology assays * MarketsandMarkets, Molecular Diagnostics Market - Forecast To 2020 ** 28

28 The world is our market Over 60 countries covered through three sale channels*: 1 Direct sales force covering Western European countries 2 Distributor contracts in place covering approx. 45 countries US commercialization partnership signed in November 2016 Announcement commercialization strategy China in 2017 Announcement commercialization strategy Japan in 2017/ / Global pharma collaborations (e.g. Merck and Amgen) Direct reps on the ground Distributors signed up Partnership under discussion * Situation as per 31 December

29 Q&A 30